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Effective antiretroviral therapy (ART) suppresses viremia
and allows immunological recovery, but the intrinsic
features of retroviral biology allow HIV infection to per-
sist despite ART. Persistent infection is primarily char-
acterized by the twin phenomenon of latent infection of
long-lived cells of the immune system, and continued
virus release from undefined cellular sources.
Of late has there been a reawakening of interest in
strategies to purge these latent reservoirs of HIV with
the goals of a drug-free remission of viremia and, ulti-
mately, virus eradication. To achieve this, therapeutics
that target host restrictions to proviral expression that
exemplify latent infection, such as epigenetic modifica-
tions of chromatin about the HIV promoter, or deficien-
cies of key host transcription factors within resting CD4
T cells, have been explored in laboratory models of
latency, and emerging humanized mouse and non-
human primate model systems.
Most clinical studies of ART intensification have thus
far shown little effect on persistent infection or persis-
tent viremia, but plans for further human studies are
underway. However, as multiple molecular mechanisms
appear to underlie the establishment and maintenance
of persistent, latent HIV infection, combined approaches
may ultimately be necessary to effectively purge residual
HIV genomes.
Beyond these near-term efforts, renewed translational
efforts seek to re-examine the possibility of transplant-
ing HIV-infected patients with cells resistant to virus
infection, alongside expanding laboratory studies to
directly excise, damage, or silence proviral genomes. It
is clear that to control the HIV pandemic, the scientific,
medical, and pharmaceutical communities must marshal
new technological and logistical approaches to sustain
innovative efforts to prevent and treat HIV, and to work
towards a cure for HIV infection.
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